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Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit colorectal neoplasia, an effect that is associated with their ability to induce
apoptosis. Although NSAIDs have been reported to inhibit NF-kB, more recent studies show activation of NF-kB by NSAIDs. NF-kB
commonly shows antiapoptotic activity and is implicated in the therapeutic resistance of cancer cells. The effects of highly COX-2-
selective NSAIDs such as NS-398 on NF-kB in colorectal tumour cells have not been reported. Therefore, we addressed whether
NF-kB has a role in NS-398-induced apoptosis of colorectal cancer cells. Treatment of HT-29 colorectal carcinoma cells with doses
of NS-398 (50–75mM) known to induce apoptosis had no effect on NF-kB for up to 48h. However after 72 and 96h NF-kB DNA-
binding activity was increased by NS-398, in parallel with apoptosis induction. NS-398-treated HT-29 cells showed increased p50
homodimer binding and an induction of p50/p65 heterodimers, as demonstrated by supershift assay. However, although NS-398
increased NF-kB DNA binding it did not increase NF-kB-dependent reporter activity and inhibition of NF-kB DNA binding did not
enhance NS-398-induced apoptosis. This indicates that NF-kB activated by NS-398 is transcriptionally inactive and is an encouraging
result for the use of COX-2-selective NSAIDs not only in chemoprevention but also as novel therapies for colon cancer.
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The term NF-kB refers to a family of dimeric transcription factors
binding a common DNA sequence motif known as the kB site. In
mammals there are 5 NF-kB family members, p50, p52, p65 (RelA),
RelB and c-Rel, which form various homo- and heterodimers. In
most resting cell types, NF-kB is sequestered in the cytoplasm via
binding to inhibitory proteins of the IkB family. Upon exposure to
stimuli such as TNF-a,I kB proteins are phosphorylated and
degraded, allowing NF-kB proteins to enter the nucleus and bind
to kB elements of target gene promoters. NF-kB is considered to
have a critical role in the regulation of apoptosis due to its ability
to activate the expression of many antiapoptotic genes, for
example, TRAF and IAP proteins, c-FLIP, Bcl-XL and A1 (reviewed
in Karin et al, 2002; Karin and Lin, 2002).
NF-kB activity varies within the colonic crypt and has been
implicated in the maintenance of colonic crypt homeostasis (Inan
et al, 2000), which relies on tight regulation of proliferation,
differentiation and apoptosis (Williams et al, 1996). Moreover, NF-
kB activity may be deregulated in colorectal cancer (Lind et al,
2001). NF-kB has been implicated in the resistance of colon cancer
cells to therapeutic agents. For example, the active metabolite
(SN38) of the colon cancer therapeutic irinotecan (CPT-11) was
shown to activate NF-kB in most colorectal cell lines in vitro.
Blocking activation of NF-kB enhanced both the cytotoxicity of
SN38 in vitro and the sensitivity of tumours to CPT-11 in a murine
colorectal cancer xenograft model (Cusack et al, 2000).
Nonsteroidal anti-inflammatory drugs (NSAIDs) show antineo-
plastic activity in the colon which appears to be due, at least in
part, to NSAID-induced apoptosis (Shiff et al, 1996; Elder et al,
1997; Piazza et al, 1997). Large population-based studies suggest
an approximately 40–50% reduction in relative risk of developing
colon cancer by chronic use of NSAIDs such as aspirin. Moreover,
sulindac reduces the size and number of colonic polyps in familial
adenomatous polyposis (FAP) patients (reviewed in Gupta and
DuBois, 2001). However, chronic use of these traditional NSAIDs
can cause gastrointestinal side effects such as bleeding and
ulceration, limiting their widespread therapeutic use against colon
cancer. Gastrointestinal side effects of NSAIDs have been linked to
a lack of selectivity in their inhibition of cyclo-oxygenase (COX)
isoforms: traditional NSAIDs inhibit the constitutive, ‘house-
keeping’ COX-1 isoform in addition to the inducible, inflamma-
tion-associated COX-2 isoform. This led to the development of
gastrointestinal-sparing COX-2-selective NSAIDs, such as celecox-
ib. Like sulindac, celecoxib also causes a reduction in the number
of colorectal polyps in FAP patients (Steinbach et al, 2000) and has
been approved in the USA as an adjunct to standard care in this
disease. Although NSAIDs are currently being evaluated for their Revised 25 June 2003; accepted 7 July 2003
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seffectiveness in the chemoprevention of colon cancer, there is also
increasing interest in their possible use in colon cancer therapy,
either in combination with existing therapeutic agents or as novel
therapeutic agents (Tebbutt et al, 2002; Trifan et al, 2002).
Although the best-characterised target of NSAIDs is COX,
several lines of evidence suggest additional, COX-independent
targets such as NF-kB (Shiff and Rigas, 1999). Although several
studies report the inhibition of stimulus-induced NF-kB by some
NSAIDs, namely aspirin, salicylate and sulindac, this is not a
property of all NSAIDs (Kopp and Ghosh, 1994; Yamamoto et al,
1999). Interestingly, several more recent papers report activation
of NF-kB by NSAIDs (Niederberger et al, 2001; Stark et al, 2001;
Moalic-Juge et al, 2002). Hence, it appears that NSAIDs can either
inhibit or activate NF-kB. NF-kB has an important role in the
regulation of apoptosis, usually showing antiapoptotic activity.
Therefore, inhibition of NF-kB by NSAIDs could theoretically
contribute to their induction of apoptosis; conversely activation of
NF-kB could potentially limit the apoptotic response. To our
knowledge no one has addressed the effect of a COX-2-selective
NSAID on NF-kB during NSAID-induced apoptosis of colorectal
cancer cells. Therefore, we examined whether NF-kB activity was
either inhibited or increased by NS-398 treatment and, if so,
whether it had a role in NS-398-induced apoptosis of colorectal
cancer cells. Since we are specifically interested in the potential
role of NF-kB in NS-398-induced apoptosis, as well as examining
cells at early time points (1–24h) normally associated with NF-kB
activation, later time points were also examined (48–96h). This is
because apoptosis induced by a number of reagents occurs
maximally between 48 and 96h in colorectal cancer cells (Bracey
et al, 1995; Elder et al, 1996). These studies could have important
implications for the use of COX-2-selective inhibitors not only in
chemoprevention but also as novel therapies for colorectal cancer,
where they may be used as single agents or in combination.
MATERIALS AND METHODS
Cell culture and treatment
HT-29 colon carcinoma cells, which express detectable levels of
COX-2 protein (Elder et al, 1997), were grown as an adherent
monolayer in T25 tissue culture flasks in DMEM supplemented
with 10% foetal bovine serum, penicillin (100Uml
 1), streptomy-
cin (100mgml
 1) and glutamine (2mM). The NSAID NS-398 is
highly selective for inhibition of COX-2 (Warner et al, 1999) and
has previously been used to investigate the effects of COX-2-
inhibition in vitro (Tsujii et al, 1998). NS-398 (Cayman, Ann
Arbor, MI, USA) was made up as a 30mM stock solution in DMSO
and stored at  201C. Tumour necrosis factor (TNF)-a (Autogen
Bioclear, Wiltshire, UK) was made up as a 100mgml
 1 aqueous
stock solution and stored at –201C. For treatment with NS-398 or
TNF-a, cells were harvested by trypsinisation (0.1% wv
 1 trypsin/
EDTA), seeded at 0.5 10
6 cells per flask and cultured for 4 days
prior to treatment. Unless otherwise stated, cell cultures were
treated in triplicate with NS-398 for up to 96h or with TNF-a for
24h (as TNF-a is a more rapid inducer of apoptosis than NS-398).
Each control and treated flask received an equal final volume of
vehicle, to a maximum of 0.01% (vv
 1) for tissue culture water and
0.25% (vv
 1) for DMSO (at this concentration DMSO does not
affect cell viability, data not shown). NS-398 was used between 50
and 75mM, as these doses induce apoptosis in HT-29 cells (Elder
et al, 1997); lower doses generally do not induce apoptosis in
colorectal cell lines (Elder et al, 2000) and higher doses (e.g.
100mM) induced a degree of nonapoptotic toxicity in HT-29 cells
after 72h (data not shown) and were therefore not routinely used.
TNF-a, a well characterised inducer of anti-apoptotic NF-kB
activity (reviewed in Karin and Lin, 2002), was used as a control
for apoptosis experiments at 100ngml
 1, a dose used by other
investigators in this cell type (Giardina et al, 1999). For reporter
assays, the dose of TNF-a was reduced to 1ngml
 1, in order to
activate a similar level of DNA binding activity to that seen with
NS-398 treatment. Cells were harvested at the indicated times for
the preparation of nuclear protein extracts or passive lysis buffer
(PLB) lysates (see below), or for cell counts. For the latter, the
attached cells (those adhered to the tissue culture flask) and the
floating cells (those having detached from the adhered monolayer)
were harvested and counted separately using a haemocytometer.
Separate aliquots of attached and floating cells were stained with
acridine orange for analysis by fluorescence microscopy (see
below).
Measurement of apoptosis
We and others have previously shown that in routine culture of
colorectal epithelial tumour cells, the majority of spontaneously
occurring floating cells are apoptotic, while the proportion of
attached cells that are apoptotic is low (o3%) (Hague et al, 1993).
Treatment with agents such as NSAIDs does not generally increase
the proportion of attached cells with apoptotic morphology but
does increase the proportion of floating cells, and this is due to
induction of apoptosis (Elder et al, 1996, 1997). Hence, in these
cases, the level of apoptosis in cultured epithelial cells can be
determined by measuring the proportion of the total cell
population that has detached from the cell monolayer. In this
study, apoptosis induced by NS-398 was determined as described
previously by Hague et al (1993). Briefly, after determining the
proportion of cells that had detached from the cell monolayer and
were floating in the medium, the fraction of these ‘floating’ cells
that were apoptotic was assessed by morphology following acridine
orange staining. Biochemical confirmation of apoptosis was
obtained by demonstration of PARP cleavage by Western blotting.
For this purpose attached cells were harvested at 96h; floating cells
were harvested at 48h and again at 96h to minimise further
degradation of the cleaved PARP protein.
Preparation of nuclear protein extracts
Nuclear protein extracts were prepared using a protocol based on
the method of Andrews and Faller (1991). Cell cultures were
washed twice and scraped into ice-cold phosphate-buffered saline
(PBS). All subsequent stages were carried out at 41C or on ice. Cells
were centrifuged (10000g, 2min) and pellets resuspended in ice-
cold buffer 1 (10mM HEPES–KOH pH 7.9, 10mM KCl, 1.5mM
MgCl2,1 m M DTT, 0.5mM PMSF and 2mgml
 1 leupeptin). Cells
were incubated for 10min to allow swelling and then lysed by
vigorous vortexing for 30s. After addition of NP-40 (final
concentration 3.75%) and a further minute of vortexing, nuclei
were pelleted by centrifugation (10000g, 1min). Nuclei were
resuspended in ice-cold buffer 2 (20mM HEPES–KOH pH 7.9,
400mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% glycerol, 1mM
DTT, 0.5mM PMSF and 2mgml
 1 leupeptin) and incubated on ice
for 20min. After centrifugation (10000g, 2min), the supernatant
(nuclear protein extract) was removed and aliquots stored at
 701C. Protein concentrations of the nuclear protein extracts were
determined using the Bradford-based BioRad protein assay
(BioRad Laboratories, Hercules, CA, USA).
Electrophoretic mobility shift assay (EMSA)
To assay DNA-binding by EMSA a double-stranded NF-kB-
binding oligonucleotide (AGTTGAGGGGACTTTCCCAGGC; Pro-
mega, Southampton, UK) was end-labelled with [g 
32P]ATP using
T4 polynucleotide kinase (Boehringer Mannheim, Germany).
Binding reactions were performed in a total volume of 20ml
Roche, East Sussex, UK containing 1mM MgCl2,1 m M KCl, 7.5%
(wv
 1) Ficoll, 8.5mM HEPES, 1mM DTT, 1mgml
 1 BSA, 1–4mg
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spoly(dI-dC) (Roche East Sussex, UK) and 1–4mg nuclear protein
extract. Reactions were incubated for 15min at room temperature,
during which time an excess of unlabelled NF-kB oligonucleotide
(see above) or unlabelled AP-1 oligonucleotide (CGCTTGAT-
GAGTCAGCCGGAA, Promega, UK) was added where appropriate
for competition assays, followed by a 5min incubation. A volume
of 2ml of end-labelled NF-kB oligonucleotide at 20000cpmml
 1
was then added and, following a further 20min room temperature
incubation, protein–DNA complexes were separated from free
oligonucleotide on a 5% nondenaturing polyacrylamide/Tris
borate EDTA gel at 150V for 2h and visualised by autoradio-
graphy. For supershift assays, 1ml of NF-kB antibody or control
IgG was preincubated for 30min at room temperature with the
nuclear extract-binding mix prior to addition of labelled NF-kB
oligonucleotide. Rabbit anti-NF-kB antibodies for supershift
analysis (p50: sc-114; p65: sc-372; p52: sc-298; c-Rel: sc-70 and
RelB: sc-226) and control IgG were all obtained from Santa Cruz
Biotechnology (USA).
Protein extracts and SDS–PAGE Western blotting
For Western blotting, cells were harvested by trypsinisation (0.1%
wv
 1 trypsin/EDTA) and counted using a haemocytometer.
Western samples were prepared from 10
6 adherent cells (for IkBa)
or from 2 10
6 each of adherent and floating cells (for PARP
cleavage). Cellular protein lysates were prepared in sample buffer
(62mM Tris-HCl (pH 6.8), 10% (vv
 1) glycerol, 5% (vv
 1)2 -
mercaptoethanol, 4% (wv
 1) SDS, 0.01% (wv
 1) bromophenol
blue) and SDS–PAGE immunoblotting carried out as described
previously (Elder et al, 2000). IkBa protein was detected using
polyclonal anti-IkBa at 1:1000 (NEB, Beverly, MA, USA). Full-
length PARP protein (118kDa) and the 85kDa apoptosis-induced
cleavage product were detected using monoclonal anti-PARP at
1:1000 (Alexis Biochemicals, Nottingham, UK). Loading and
transfer were controlled by repeat probing with anti-a-tubulin
(Sigma, Dorset, UK) at 1:20000. Membranes were subsequently
probed with an anti-rabbit (for IkBa) or an anti-mouse (for PARP
and a-tubulin) secondary antibody conjugated to horseradish
peroxidase (Sigma) at 1:1000 or at 1:2000 for use following anti-
a-tubulin. Bound antibodies were detected using enhanced
chemiluminescence (Kirkegaard and Perry, Gaithersburg, MD,
USA). If necessary, membranes were stripped by incubation for
30min at 501C in a solution of 62mM Tris-HCl pH 6.7, 2% SDS and
100mM 2-mercaptoethanol.
Adenovirus-driven overexpression of IjBa
A recombinant adenovirus (rAd.IkBa) carrying the wild-type
porcine IkBa gene fused to a nuclear localisation signal was used to
overexpress IkBa protein in HT-29 cells (Wrighton et al, 1996).
Porcine IkBa is strongly homologous to human IkBa (de Martin
et al, 1993) and this adenoviral vector has previously been shown
to inhibit activation of NF-kB in human cells (Liu et al, 2001).
rAd.IkBa was a kind gift from Dr Ranier de Martin (Department of
Vascular Biology and Thrombosis Research, University of Vienna,
Austria). As a control for infection experiments, a recombinant
adenovirus carrying the bacterial LacZ gene (rAd.bgal) was used
(Wilkinson and Akrigg, 1992). rAd.bgal was a kind gift from Dr G
Wilkinson (Department of Cardiology and Medicine, University of
Wales College of Medicine, Heath Park, Cardiff, UK). Cells were
infected with viral vectors in normal growth medium for 4h and
then allowed to recover overnight in normal growth medium prior
to experimental treatment the following day.
Cell transfection
For NF-kB reporter assays, cells were transiently transfected
with either the NF-kB reporter plasmid pNF-kB-TA-luc or with
the control reporter plasmid pTA-luc (Clontech, Oxford, UK).
pNF-kB-TA-luc contains four copies of a consensus NF-kB binding
sequence (GGGAATTTCC) in addition to a minimal promoter
(PTA, the TATA box from the herpes simplex virus thymidine
kinase promoter) located upstream of the firefly luciferase (luc)
gene. The consensus NF-kB binding sequences are absent from the
control vector pTA-luc. All transfections also included the renilla
luciferase vector pRL-SV40 (Promega, UK) as an internal control
for transfection efficiency.
For transient transfection, HT-29 cells were seeded at 0.5 10
6
cells per T25 flask. At 3 days after seeding, triplicate flasks were
cotransfected with one of the two reporter constructs (pTA-luc or
pNF-kB-TA-luc) and with the renilla construct (pRL-SV40) in a
ratio of 50:1. Each flask was incubated for 6h with 2mg of plasmid
DNA and 5ml of lipofectAMINE 2000 (Invitrogen) diluted in opti-
MEM serum-free medium according to manufacturers’ instruc-
tions. Following transfection, cells were allowed to recover
overnight in 10% DMEM prior to experimental treatment as
described above. A dose of 75mM NS-398 was used for reporter
assays in order to maximise the activation of NF-kB DNA binding
in these experiments.
Luciferase reporter assay
At the specified time, cells were washed in PBS and lysates
prepared in 1  PLB Promega, UK) according to manufacturers’
instructions. Reporter activity was measured using the Dual-
Luciferase reporter assay system (Promega, UK) and a Jade
Luminometer (Labtech, UK) set for a 10s read. Sample readings
were corrected for background autoluminescence using untrans-
fected cells as a control.
RESULTS
NS-398 increases NF-jB DNA-binding at late but not early
time points in colorectal cancer cells
Since NF-kB can limit the response to therapeutic apoptosis-
inducing agents, we determined whether NF-kB was activated or
inhibited during NS-398-induced apoptosis in colorectal cancer
cells. Preliminary experiments were performed to confirm that NS-
398 induces apoptosis in HT-29 cells, as previously reported (Elder
et al, 1997). Doses of 50 and 75mM NS-398 increased the
proportion of HT-29 cells that were detached and floating in the
culture medium at 72 and 96h (Figure 1A), with no significant
effect at earlier time points (data not shown). Our previous studies
have shown that these floating cells are apoptotic (Hague et al,
1993; Elder et al, 1997). The apoptotic nature of floating cells from
control and NS-398-treated cultures was confirmed by acridine
orange staining as in Elder et al (1997) (data not shown). Further
confirmation of apoptosis was obtained by Western blotting for
PARP protein, a target of activated caspases during apoptosis.
Attached (nonapoptotic) cells contained intact 118kDa PARP
protein. However, floating cells showed no evidence of intact
PARP, containing only the cleaved 85kDa PARP fragment, a
characteristic marker of apoptosis (Figure 1B).
Having confirmed that NS-398 induces apoptosis of HT-29 cells
in this system, nuclear extracts were prepared from these cultures
and the levels of NF-kB DNA-binding activity were investigated.
No effect of up to 100mM NS-398 on NF-kB DNA-binding was
observed at 1, 6, 12 or 24h and NS-398 did not alter NF-kB-
dependent reporter activity after 24h of treatment (data not
shown). However, NF-kB DNA binding was increased by 50 and
75mM NS-398 at 72 and 96h (Figure 2A, left panel), when NS-398-
induced apoptosis is maximal. NF-kB DNA-binding was inhibited
by an excess of unlabelled NF-kB oligonucleotide but not
by unlabelled AP-1 oligonucleotide (Figure 2A, right panel).
Concentration not a volume 50 and 75mM NS-398 did not increase
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sNF-kB DNA-binding at 48h (data not shown), suggesting that NF-
kB is not a cause of NS-398-induced apoptosis. Activation of NF-
kB at 72 and 96h was associated with a slight but reproducible
decrease in IkBa levels at 72h and a marked decrease after 96h of
NS-398 treatment (Figure 2B). In order to determine the subunit
composition of NF-kB activated by NS-398, supershift EMSA
analysis was carried out. NF-kB DNA-binding activity in controls
was diminished in intensity and supershifted only by anti-p50
antibodies (Figure 3), indicating a composition of p50/p50 dimers.
NS-398 enhanced p50/p50 NF-kB DNA-binding activity and
induced a second, more slowly migrating band. The latter was
decreased in intensity on incubation with both anti-p50 and anti-
p65 antibodies (Figure 3), indicating that this upper band
represented p50/p65 heterodimers (this particular anti-p65 anti-
body did not produce a supershifted band, presumably due to
interference with binding of p65-containing NF-kB to labelled
oligonucleotide). Similar results were obtained in supershift
analysis of 72h samples treated with 60mM NS-398, where a lower
p50/p50 band and an upper p50/p65 band were detected. Again
control samples contained only p50/p50 activity (data not shown).
Further evidence for the involvement of p50 and p65 subunits was
obtained using an ELISA-based method (see, for example, Bochkov
et al, 2002). This showed increased binding of p50 and p65 to an
NF-kB consensus oligonucleotide in NS-398-treated HT-29 cells
(data not shown).
In summary, the COX-2-selective NSAID NS-398 has no effect
on NF-kB DNA-binding activity between 1 and 48h, suggesting
that NF-kB is unlikely to be a cause of NS-398-induced apoptosis
(observed maximally between 72 and 96h). However, NF-kB DNA-
binding (p50/p50 and p50/p65) was increased in NS-398 treated
cells at 72 and 96h: this could potentially limit the induction of
apoptosis by NS-398.
Inhibition of NF-jB activation following NS-398 treatment
does not enhance apoptosis in HT-29 cells
Activation of NF-kB is reported to limit the efficacy of apoptosis
induction by a number of anticancer drugs (reviewed in Barkett
Figure 1 Induction of apoptosis by the COX-2-selective NSAID NS-
398 in colorectal carcinoma cells. (A) N-398 induces apoptosis in HT-29
cells. HT-29 cells were treated with 0mM (vehicle only), 50mM or 75mM NS-
398. At 72 and 96h, both attached and floating cells were harvested and
counted and floating cell yields were calculated as a percentage of total cell
yields. Floating cell yield data are means7s.e.m. of three independent
repeat experiments carried out in triplicate. Apoptotic morphology of
floating cells was confirmed by acridine orange staining (as in Elder et al,
1997). (B) Floating cells show the absence of intact PARP and the presence
of cleaved PARP, a biochemical marker of apoptosis. HT-29 cells were
treated with 0mM (vehicle) or 75mM NS-398 for 96h. Lysates from 2 10
6
attached and floating cells were analysed by Western blotting for PARP
expression and cleavage.
Figure 2 Activation of NF-kB DNA-binding activity in colorectal
carcinoma cells by the COX-2-selective NSAID NS-398. (A) NS-398
induces NF-kB DNA-binding activity in HT-29 cells. HT-29 cells were
treated with 0, 50 or 75mM NS-398 for 72 or 96h. At the indicated time
points, nuclear extracts were prepared and 1mg analysed by EMSA.
Competition assay (right-hand panel): þNF-kB¼plus unlabelled NF-kB
oligonucleotide (specific competitor), þAP-1¼plus unlabelled AP-1
oligonucleotide (nonspecific competitor),  ¼no oligonucleotide. The final
lane contains no nuclear protein extract as a negative control. (B) NS-398
downregulates IkBa levels in HT-29 cells. HT-29 cells were treated with 0,
50 or 75mM NS-398 for 72 or 96h. Whole-cell lysates from 10
6 attached
cells were analysed by Western blotting for IkBa expression levels at 72
and 96h. Blots were probed with an a-tubulin antibody as a control for
equal loading and transfer. Results shown are representative of those
obtained in three independent repeat experiments.
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sand Gilmore, 1999). We next investigated whether blocking the
activation of NF-kB (using the adenoviral IkBa vector rAd.IkBa)
sensitised colorectal cells to induction of apoptosis by NS-398. For
NS-398 experiments, cells were infected with rAd.IkBa at the
maximum titre that did not itself result in activation of NF-kBa t
72h, which was 10MOI. A dose of 60mM NS-398 was used, as
preliminary experiments suggested that this gave optimal apopto-
sis induction in virus-infected cells. Infection of HT-29 cells with
rAd.IkBa increased IkBa expression (Figure 4A, lanes 3 and 4) and
gave a partial inhibition of NF-kB activity induced by NS-398
(Figure 4B, compare lane 4 with lane 2). However, infection with
rAd.IkBa did not increase the levels of apoptosis observed in NS-
398-treated HT-29 cells compared to infection with the control
vector rAd.bgal (Figure 4C, compare bar 4 with bar 2).
Inhibition of NF-kB has been shown to enhance TNF-a-induced
cytotoxicity in a number of cell types, including intestinal
epithelial cells (Han et al, 2000; Potoka et al, 2000). Therefore, in
order to determine whether a partial inhibition of NF-kBa s
observed in NS-398 experiments was sufficient to enhance
apoptosis, control experiments were carried out using a second
inducer of NF-kB, TNF-a. A dose of 50MOI rAd.IkBa was used in
order to give a similar degree of inhibition of NF-kB and increase
in IkBa expression to those seen in NS-398 experiments. Infection
of HT-29 cells with rAd.IkBa increased IkBa expression (Figure 4A,
lanes 7 and 8) and gave a partial inhibition of NF-kB activity
induced by TNF-a (Figure 4B, compare lane 8 with lane 6).
Infection with rAd.IkBa did not increase the levels of apoptosis
observed in untreated HT-29 cells compared to infection with the
control vector rAd.bgal (Figure 4C, compare bar 7 with bar 5).
However, infection with rAd.IkBa enhanced apoptosis induced by
TNF-a approximately two-fold (range 1.9- to 2.5-fold) (Figure 4C,
compare bar 8 with bar 6).
NS-398-induced NF-jB is not active at the level of
transcription
One possible reason why inhibition of NF-kB did not enhance NS-
398-induced apoptosis is that NF-kB activated by NS-398 is
transcriptionally inert. In order to test this hypothesis, NF-kB
reporter assays were carried out. HT-29 cells were transiently
transfected with either the NF-kB-luciferase reporter pNF-kB-TA-
luc or with a control vector lacking NF-kB sites, pTA-luc. Reporter
activity in HT-29 cells transfected with pTA-luc was consistently of
a very low level (Figure 5A and B, first two bars). HT-29 cells
transfected with pNF-kB-TA-luc showed some constitutive NF-kB
reporter activity (Figure 5A and B, third bar from left), consistent
with the NF-kB DNA-binding activity observed under these
conditions (Figure 5C, first and third lanes). However, treatment
of HT-29 cells with NS-398 did not increase NF-kB-dependent
reporter activity (Figure 5A, final bar). This was in contrast to
TNF-a which, at doses inducing a similar increase in DNA-binding
activity (Figure 5C, final lane), gave more than a two-fold increase
(range 2.5- to three-fold) in NF-kB-dependent transcription
(Figure 5B, final bar).
Figure 3 The COX-2-selective NSAID NS-398 induces NF-kB DNA-
binding activity in the form of p50/p50 and p50/p65 in HT-29 cells. HT-29
cells were treated with 0 or 50mM NS-398 for 96h. Nuclear extracts were
prepared and 4mg analysed by supershift EMSA in the presence or absence
of antibodies to NF-kB proteins p50, p65, p52, c-Rel or RelB or control
IgG. The p50 antibody supershifts both bands, whereas the anti-p65
antibody only affects the upper band, suggesting that the lower band
consists of p50/p50 and the upper band of p50/p65. The p65 antibody
does not produce a supershifted band, presumably due to interference
with DNA binding. This experiment has also been carried out using
samples treated with 60mM NS-398 for 72h with equivalent results.
Figure 4 Partial inhibition of NS-398-induced NF-kB DNA-binding
activity does not enhance apoptosis induction in HT-29 cells. HT-29 cells
were infected with 10MOI (for NS-398 experiments; left-hand panel) or
50MOI (for TNF-a experiments; right-hand panel) of either the control
vector rAd.bgal or rAd.IkBa and treated the following day with 60mM NS-
398 for 72h or 100ngml
 1 TNF-a for 24h (as TNF-a is a more rapid
inducer of apoptosis). (A): Increased expression of IkBa in HT-29 cells
infected with rAdIkBa. Whole cell lysates from 10
6 attached cells were
prepared and analysed by Western blotting for IkBa expression levels.
Blots were probed with an a-tubulin antibody as a control for equal loading
and transfer. (B): Inhibition of NF-kB DNA binding by rAdIkBa. Nuclear
protein extracts were prepared and 1mg analysed by EMSA. (C): Infection
with rAd.IkBa potentiates apoptosis induced by TNF-a but not NS-398.
Both attached and floating cells were harvested and counted. Floating cell
yields were calculated as a percentage of total cell yields and are shown as
mean7s.d. Results shown in panels A–C for NS-398 and for TNF-a are
from within the same experiment and are representative of two
independent experiments carried out in duplicate. 1¼rAd.bgal;
2¼rAd.bgalþNS-398; 3¼rAd.IkBa;4 ¼rAd.IkBa þNS-398;
5¼rAd.bgal; 6¼rAd.bgalþTNF-a;7¼rAd.IkBa;8¼rAd.IkBa þTNF-a.
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DNA binding at early time points (1–48h) but does at the later
time points of 72 and 96h. However, although NS-398 increases
NF-kB DNA binding at the later time points, it does not increase
NF-kB-dependent reporter activity and inhibition of NF-kB DNA-
binding does not enhance NS-398-induced apoptosis, indicating
that NF-kB activated by NS-398 is transcriptionally inert and is not
involved in NS-398-induced apoptosis.
DISCUSSION
Although NSAIDs have recently received much attention as
promising colon cancer chemopreventives, increasing evidence
indicates that they may also be used as a novel therapy, either
alone or in combination with other agents (Tebbutt et al, 2002;
Trifan et al, 2002). This stems from the ability of NSAIDs to inhibit
invasion and angiogenesis and induce apoptosis, indicating the
importance of COX-2 in metastasis (reviewed in Cao and Prescott,
2002). Their use in a therapeutic setting would justify the use of
relatively high doses of NSAIDs, which are believed to have both
COX-dependent and COX-independent effects (reviewed in Turini
and DuBois, 2002). It is of interest to note that a significant
number of colorectal tumours do not express COX-2 protein and
therefore COX-2-independent effects of NSAIDs could be particu-
larly important in this group of tumours (Elder and Paraskeva,
1998).
The induction of apoptosis is an important mechanism of action
of anticancer agents and activation of NF-kB by such agents can
contribute to therapeutic resistance of cancer cells. Nonsteroidal
anti-inflammatory drugs induce apoptosis in colon cancer cell
lines both in vivo and in vitro. Therefore, in vitro induction of
apoptosis can be used to highlight key pathways involved in the
apoptotic response of colorectal cancer cells to COX-2-selective
NSAIDs (Elder et al, 2002). Although NSAIDs have been reported
to inhibit NF-kB (Kopp and Ghosh, 1994; Yamamoto et al, 1999),
more recent studies report activation of NF-kB by NSAIDs
(Niederberger et al, 2001; Stark et al, 2001; Moalic-Juge et al,
2002). To our knowledge there are no data concerning the effect of
highly COX-2-selective NSAIDs on NF-kB activity in colorectal
cancer cell lines. Due to our specific interest in the potential role of
NF-kB in NS-398-induced apoptosis, which is maximal between 72
and 96h, we examined these later time points in addition to earlier
time points (1–24h) normally associated with NF-kB activation.
The results presented in this study indicate that NS-398 treatment
causes a delayed activation of NF-kB DNA-binding, but not NF-
kB-dependent transcriptional activity in colon cancer cells. This is
based on the following observations: treatment of colorectal cells
with NS-398 causes a delayed and sustained activation of NF-kB
DNA-binding activity in parallel with the induction of apoptosis.
However, the inhibition of NF-kB DNA binding did not enhance
NS-398-induced apoptosis of colon cancer cells. Consistent with
this finding, NS-398 treatment did not drive transcription from an
NF-kB-dependent reporter construct. In contrast to NS-398, the
well-characterised cytokine TNF-a induced both NF-kB DNA
binding and transcriptional activity, which protected TNF-a-
treated cells against apoptosis induction.
The mechanism by which NS-398 activates NF-kB DNA binding
in HT-29 cells is not clear. However, NS-398 is known to activate
the MEK/ERK pathway in HT-29 cells and this precedes activation
of NF-kB as ERK activation is seen from 24h onwards (Elder et al,
2002). One target of ERK activity is the p90 ribosomal S6 kinase
(p90
rsk), a serine/threonine kinase that can phosphorylate IkBa at
serine 32 (Ghoda et al, 1997; Schouten et al, 1997). Therefore,
activation of NF-kB by NS-398 may involve the MEK/ERK
pathway.
Several possible explanations may account for the lack of NF-
kB-dependent transcription in response to NS-398. For example,
NS-398 may induce a protein or proteins that can inhibit the
transcriptional activity of NF-kB without interfering with DNA
binding. Activation of NF-kB DNA binding but not transcriptional
activity, has been observed in response to both UV light and the
anthracycline MEN 10755 (Campbell et al, 2001, Camarda et al,
2002). In both cases the lack of NF-kB transcriptional activity
could be attributed to increased levels of wild-type p53 protein
leading to competition for the transcriptional coactivator proteins
CBP/p300 (Webster and Perkins, 1999). This mechanism is,
however, unlikely to be relevant here as HT-29 cells express high
levels of mutant p53 (Rodrigues et al, 1990). Par-4 and c-myc have
also been reported to inhibit NF-kB at the level of transcription but
not DNA-binding (Nalca et al, 1999; You et al, 2002). However, we
were unable to demonstrate a significant increase in expression of
either of these proteins following NS-398 treatment of HT-29 cells
(results not shown), suggesting that the lack of transcriptional
Figure 5 NS-398-induces NF-kB DNA-binding activity but not
transcriptional activity in HT-29 cells. HT-29 cells were transfected with
either the firefly luciferase reporter vector pNF-kB-TA-luc or with the
control vector pTA-luc lacking NF-kB binding sites. All transfections also
included the constitutively expressed renilla luciferase vector pRL-SV40 and
hence firefly luciferase readings were normalised to renilla luciferase activity
in order to control for transfection efficiency. (A) NS-398 does not
increase NF-kB-dependent transcriptional activity in HT-29 cells. Cells
transfected with pTA-luc or pNF-kB-TA-luc were then treated with 0
(vehicle) or 75mM NS-398 for 72h. After this time, PLB lysates, were
prepared and assayed for firefly and renilla luciferase activities. Lumines-
cence data are expressed as mean firefly:renilla luciferase ratios7s.d. of
three independent experiments and within each experiment samples were
assayed in triplicate. (B) and (C) TNF-a activates NF-kB-dependent
transcriptional activity at doses inducing a similar NF-kB DNA-binding
activity to 75mM NS-398 in HT-29 cells. (B) Cells transfected with pTA-luc
or pNF-kB-TA-luc were treated with a range of doses of TNF-a for 24h.
After this time lysates were prepared and assayed for firefly and renilla
luciferase activities. Luminescence data are expressed as mean firefly:renilla
luciferase ratios7s.d. from one representative of three independent
experiments carried out in triplicate (means were not taken in this case due
to different activities between batches of TNF-a necessitating the use of
differing doses of TNF-a between experiments). (C) Nuclear protein
extracts (from pNF-kB-TA-luc-transfected cells) were prepared using
parallel flasks to those from (A) and (B) and analysed by EMSA for each of
the three independent experiments.
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induction of these proteins. It has recently become apparent that
NF-kB activity is controlled not only at the level of IkB degradation
but also at the level of transcriptional activity, involving the direct
post-translational modification of NF-kB proteins. For example,
protein kinase A (PKA) is reported to phosphorylate p65 at serine
276, enhancing the interaction of p65 with the transcriptional
coactivator CBP/p300 (Zhong et al, 1998). Hence, it is possible that
although NS-398 induces NF-kB DNA-binding, it may be unable to
stimulate the post-translational modifications of NF-kB subunits
required for full transcriptional activity.
In summary, our study demonstrates that, while capable of
activating NF-kB DNA binding, the NSAID NS-398 does not
increase NF-kB-dependent transcriptional activity in colon cancer
cell lines. This suggests that, in contrast to apoptosis induced by
other agents, activation of NF-kB is unlikely to limit apoptosis
induced by NS-398. The lack of induction of NF-kB transcriptional
activity by NS-398 is a promising outcome for the use of COX-2-
selective NSAIDs not only in chemoprevention but also as novel
therapies. The inability of NS-398 to increase NF-kB-dependent
transcription may be of particular importance when considering
the use of COX-2-selective inhibitors in combination with other
therapeutic agents, particularly those that act through the
induction of apoptosis.
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